Wednesday brought a fresh batch of analyst initiations, and when Wall Street firms start covering a stock, it's usually because they think there's a story worth telling. This week's lineup spans from a major industrial gases player to a handful of smaller biotech names that analysts believe deserve attention.
Leading the pack in terms of market cap, CICC analyst Shanshan Shen launched coverage on Linde plc (LIN) with an Outperform rating and a $510 price target. That's a meaningful vote of confidence considering the stock closed at $408.79 on Tuesday, suggesting the analyst sees about 25% upside ahead for the industrial gases giant.
Over in biotech land, HC Wainwright analyst Brandon Folkes had a busy day, initiating coverage on two companies. First up was Traws Pharma, Inc. (TRAW) with a Buy rating and an $8 price target. The stock closed at $2.16 on Tuesday, which means Folkes sees substantial room to run if the thesis plays out. He also started coverage on Pelthos Therapeutics Inc. (PTHS) with a Buy rating and a $60 price target, compared to Tuesday's closing price of $25.14.
Canaccord Genuity analyst John Newman joined the party by initiating coverage on Compass Therapeutics, Inc. (CMPX) with a Buy rating and a $10 price target. The stock closed at $5.22 on Tuesday, so Newman's call implies he sees potential for the shares to nearly double from current levels.
Rounding out Wednesday's initiations, LifeSci Capital began coverage on Oculis Holding AG (OCS) with an Outperform rating and a $55 price target. Oculis shares closed at $18.79 on Tuesday, giving the analyst's target nearly triple the upside if the company can execute on its vision.
These initiation calls represent the first formal opinions from these analysts on these particular stocks, which typically means they've completed deep research and believe there's a compelling investment case. Whether you're looking at established names like Linde or smaller biotech plays, these fresh perspectives offer a window into what certain corners of Wall Street think about where these companies are headed.
